Drugs / TRAXIVITUG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04294472 | Aug 2020 → Feb 2022 | polyomavirus infectious disease | Vera Therapeutics, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03456999 Comparator | Oct 2018 → Jul 2020 | BK-virus nephropathy | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRAXIVITUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314887 ↗ |
| Known as | MAU868 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03456999 ↗ |
| Modality | Protein / enzyme biologic | “BKV-specific, pan-serotype neutralizing antibody” NCT03456999 ↗ |
| Route | Intravenous | “MAU868 infused i.v. over 1 hour.” NCT03456999 ↗ |